HC Wainwright reiterates Sell for Sarepta Therapeutics stock

Published on 10/07/2026 at 01:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HC Wainwright set a USD 5.00 target on October 5, 2026. Sarepta Therapeutics stock had EUR 15.37 at the October 6, 2026 prior close.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics, Inc. (US8036071004) had its Sell rating reiterated by HC Wainwright in a report released on October 5, 2026, with a USD 5.00 price target, according to MarketBeat. The rating arrived after Sarepta presented new ELEVIDYS data at the 2026 World Muscle Society Annual Congress on September 30, 2026, according to Sarepta Therapeutics.

USD 5.00 target shows the divide

HC Wainwright's target sits well below the USD 17.50 closing reference cited for October 2, 2026 in the analyst coverage. The same MarketBeat report says the stock had a one-year range of USD 14.68 to USD 25.32 and a market capitalization of USD 1.83 billion.

That valuation gap reflects a sharply divided analyst picture. MarketBeat counted seven Buy ratings, seven Hold ratings and seven Sell ratings, with a consensus target of USD 22.71, while HC Wainwright retained the most bearish published target in the report.

Second-quarter revenue fell 34.30 percent

Sarepta's second-quarter 2026 revenue was USD 401.25 million, according to Markets Insider. That compared with USD 611.09 million in the second quarter of 2025, a decline of 34.30 percent, while the company posted a GAAP net loss of USD 4.89 million.

The results also contained a counterweight to the revenue decline. MarketBeat reported quarterly earnings per share of USD 0.64 against a USD 0.22 consensus estimate, a USD 0.42 beat, but the report also cited a negative net margin of 13.48 percent.

ELEVIDYS data meet a lower valuation

The September 30 presentation adds clinical evidence to Sarepta's commercial story, but the analyst spread shows that investors continue to assign sharply different values to the pipeline and ELEVIDYS uptake. The USD 5.00 target from HC Wainwright contrasts with Wells Fargo's Buy rating and USD 38.00 target dated October 2, 2026, as reported by Markets Insider. For investors, the key tension is measurable: falling quarterly revenue and a negative margin sit alongside earnings above consensus and new clinical data.

Prior close remains EUR 15.37

The Lang & Schwarz prior close was EUR 15.37 on October 6, 2026. Sarepta Therapeutics is listed on Nasdaq under ticker SRPT, and its market capitalization was USD 1.8 billion as of October 6, 2026.